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ABSTRACT 
 
This paper explores the case of market integration and price convergence in the European Union, 
specifically in the pharmaceutical industry. The EU has been experiencing market integration 
since 1992, through the removal of trade barriers, the establishment of a single market, and the 
reduction of exchange rate volatility.  In addition, there have been several structural reforms in 
product markets designed to increase competition, monitor cross-country price differences and 
increase transparency.  One anticipated effect of market integration is price convergence, because 
of the reduced potential for price discrimination across the EU.  This paper is aimed to analyze 
market integration and price convergence in the European pharmaceutical market, which is the 
fifth largest industry in the EU.  Since 1985, many EU directives have been adopted to achieve a 
single EU-wide pharmaceutical market, with the aim of enhancing the quality of life for European 
citizens and the European pharmaceutical industry’s competitiveness and research and 
development capability.  Using annual 1994–2003 IMS Health panel data from five EU countries 
on prices of drugs used to treat cardiovascular disease and controlling drug and market 
characteristics; this paper examines how the integration process has affected cross-country drug 
price dispersion in the EU through the preliminary results from the panel data unit root test. 
Finally, the results show some evidence of price convergence in the pharmaceutical market, with 
long term price differences arising from country fixed effects. 
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INTRODUCTION AND LITERATURE REVIEW 
 
his paper explores the case of market integration and price convergence in the European Union, 
specifically in the pharmaceutical industry. The European Commission recognizes the importance of 
price competition and price convergence through a single market program:  “The removal of barriers 
and the freedom of supply which businesses will enjoy as a result of the single market program should lead, through 
increased competitive pressure, to some downward convergence of prices of benefit to the customer.  From the point 
of view of producers, the competitive pressure will be exerted first and foremost on price-cost margins, particularly 
in those sectors in which they held a certain monopoly power or position.  Producers will also be induced – urged on 
by pressure on their margins – to become more efficient and thus cut their production and distribution costs.  The 
increased pressure which will be brought to bear in this way on costs and price-cost margins will be a powerful 
means of causing prices to converge on levels more consistent with economic and technical efficiency” (DRI 1996).  
Furthermore, the EU Treaty also requires the Commission and the European Central Bank to report on convergence 
at the macroeconomic level because convergence will ensure that a single EMU interest rate is appropriate for all 
participants. Moreover, when the EMU is hit by a macroeconomic shock, a high degree of convergence limits 
asymmetric economic developments at the country level, which can no longer be addressed by adjusting the 
exchange rate (European Commission 2004).  Finally, price convergence indicates the evolution of product market 
integration.  
 
 
T 
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DRI (1996) showed a trend towards price convergence in the EU-12 during 1980–1993 using price indexes 
for detailed product and service categories collected by Eurostat.  This trend was more pronounced for consumer 
and equipment goods than for energy, services, and construction.  The convergence in consumer products and 
services has accelerated since the single market program.  Convergence has been comparatively greater for the three 
1989 entrants (Greece, Portugal and Spain) than the EU-9, which may reflect a catch-up effect of integration.  The 
product categories with the greatest convergence were in highly traded (more open) industries.  Four products and 
services related to health care had the highest price disparities in 1993.  The study concluded that 78 
product/services categories, representing 60% of EU private consumption expenditures, had significant price 
convergence, compared to only eight cases of price divergence (DRI 1996). 
 
Using Eurostat panel data for 1975–1995 on monthly consumer price indexes for 12 EU countries, 
Sosvilla-Rivero and Gil-Pareja (2004) examined how European market integration has affected cross-country price 
dispersion in the EU.  They used the Levin and Lin (1992) convergence equation to test for unit roots with panel 
data, with Germany as the benchmark country based on its central role in the EMS.  The estimated speed of 
convergence (β) for the general CPI was –0.006, which implies a half life of a shock of 115 months. The highest 
estimated β was for fruits (–0.073) with a half life of 9 months, and the lowest estimated β was for recreation (–
0.001) with a half-life of 693 months. The study concluded that there was empirical evidence of price convergence, 
especially for traded goods. The study failed to obtain such evidence in the cases of non-tradable goods or goods 
that are subject to special taxes or regulations. 
 
A similar study by Gil-Pareja and Sosvilla-Rivero (2004) examined the degree and recent evolution of 
export-price dispersion between 1988 and 2001 among seven EU countries (Belgium-Luxembourg, France, 
Germany, Italy, the Netherlands, Spain and the UK) for a number of eight-digit products using the Eurostat data.  
The data set was based on the annual free on board (f.o.b.) value and quantity of exports to selected OECD 
countries.  It is expected that relatively fixed exchange rates established by EMS would result in price convergence 
by imposing price discipline among its members.  As a measure of export-price dispersion, they used the coefficient 
of price variation, i.e. the ratio of the standard deviation to the mean, which is invariant to changes of scale.  To 
assess price convergence, the time series of variation for each source country-product pair were regressed on a 
constant and a linear time trend. The results of the study showed that export-price dispersion was usually lower in 
the sample than across OECD countries. There was little evidence of convergence, but this was also stronger across 
the EU countries.  The conclusion was that although monetary stability may aid price convergence, it does not 
necessarily lead to complete convergence. 
 
Two other studies, Rogers (2001) and Rogers et al. (2001), found direct evidence of price convergence in 
Europe, using European price indices from actual prices of 168 goods and services, in 26 cities, in 18 countries, 
between 1990 and 1999.  Prices became less dispersed in the euro area and convergence was evident for traded 
goods, more in the first half of the 1990s than the second half.  By some measures, traded goods price dispersion 
across the euro area was close to that across US cities. 
European Commission (2004) also concluded that there is a continuing convergence of prices of recent 
entrants towards the considerably higher levels in the EU-15, again due to the catching-up process and price 
deregulation. As a result, price convergence in the new member states has been faster than in the EU-15.  
 
Camarero et al. (2000) examined price and inflation convergence between three European countries (Italy, 
Spain and the UK). The results rejected long-run convergence in all cases but found that prices catch up with the 
European average.  
 
There have been several studies of price convergence in specific EU product markets, particularly the car 
market (Gaulier and Haller 2000;Goldberg and Verboven 2001; 2004;Verboven 1996).  Goldberg and Verboven 
(2005) investigated the relationship between integration and price convergence using panel data on car prices 
between 1970 and 2000.  Approximately 150 vehicles per year and five markets [Belgium (the benchmark country), 
France, Germany, Italy and the UK] were included.  They found strong evidence of both the absolute and relative 
versions of the Law of One Price.  Hedonic regressions were estimated to control for possible variations in 
characteristics of models across countries, and these quality-adjusted prices were used to form the dependent 
variable for the Levin and Lin (1992) convergence equations.  The relative version of the Law of One Price implied 
Journal of Business & Economics Research – October 2011 Volume 9, Number 10 
© 2011 The Clute Institute  37 
half lives of shocks between 1.3 and 1.6 years.  
 
Kerem et al. (2005) estimated the convergence of health care expenditures in the EU using β- , σ- , γ- 
convergence for the 1992–2001 period.  The study demonstrated that even though economic integration has 
facilitated economic growth, the EU’s enlargement process has not brought about harmonization of health care 
expenditures in the EU-8 new member states (Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, 
Slovakia, and Slovenia).  It would take approximately three years for health care expenditures as a share of GDP in 
the EU-8 countries to move halfway to the EU-15 average.  
 
Lastly, Ratfai (2006) examined price convergence among geographically close locations that share the 
same currency, using a sample of highly disaggregated product level prices of very narrowly defined homogeneous 
items in Hungary.  Employing a series of panel data unit root tests using the Levin et al. (2002) procedure, the 
results showed price differentials fading away quickly, with an estimated half-life of between 2.2 and 12.0 months 
and a median half-life of 4.0 months.   
 
Price convergence in pharmaceutical markets has not been subject to empirical investigation, thus this 
paper attempts to do so. However, the pharmaceutical industry has been placed high among the most sensitive 
sectors of the single market program (Allen, et al. 1998). 
 
METHODOLOGY 
 
It is expected that market integration of sourcing, retailing and distribution contributes to price convergence 
among EU countries (Coopers 1996). However, because the relationship between European integration and price 
convergence depends on many different structural, behavioral, and policy factors that differ across markets, price 
convergence patterns are expected to vary by industry.  The objective of this paper is to preliminary test the 
hypothesis of price convergence in the EU pharmaceutical industry. The methods of controlling for the quality and 
market characteristics and the model specifications are adopted from Goldberg and Verboven (2005) and Danzon 
and Chao (2000).   
 
Data 
 
The data for this paper represent selected cardiovascular pharmaceuticals. They come from IMS Health, 
which collects and reports sales and price data at the level within the pharmaceutical market supply and distribution 
chain that provides the most accurate information for a country (IMS 2005a).  Of the 29 IMS Health three-digit 
CVD categories, this analysis samples the eight studied by Dickson and Jacobzone (2003).  These categories cover a 
wide range of both newer and older innovations that form the core of pharmacotherapy for CVD. 
 
The five countries in the sample are Germany, the UK, Italy, Spain, and France.  These countries have the 
largest pharmaceutical production and sales in the EU-15 (OECD 2003) and represent the five largest 
pharmaceutical markets in the world after the US and Japan (Pammolli, et al. 2004). Restricted as described above, 
the IMS Health data include 658 molecules (119 for France, 177 for Germany, 135 for Italy, 119 for Spain and 108 
for the UK) for the 1994–2003 period. Different data sets are constructed for different parts of the analysis. 
Depending on the benchmark country, an average of 50% of retail sales do not match bilaterally and thus are not 
included.   
 
Quasi-hedonic price regressions are based on a balanced panel of all 379 molecules over 10 years and five 
countries, yielding sample sizes of 3,790. To form the dependent variable in the price convergence regressions, two 
distinct bilateral matched samples are constructed, with 3,210 and 2,940 observations depending on whether 
Germany or Spain, respectively, serves as the base country.  Another sample is constructed to form the dependent 
variable measured in deviations from the cross country average.  This sample includes all 379 molecules and has 
3,790 observations.  
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Definition of Price in the IMS Data 
 
Prior to Danzon (1999), cross country studies compared the price for a single drug pack in the base country, 
but this pack may not be typical or even available in other countries (Berndt 2000).  Danzon recognized that samples 
using only comparison packs with the same ingredient, manufacturer, brand name, dosage form, pack size and 
strength in each country will exclude generic and OTC products.  These are likely close substitutes for originator 
and prescription drugs, respectively, so their omission will potentially result in unrepresentative samples (Hellerstein 
1998), a problem that might be exacerbated by not including all forms and strengths (Ellison, et al. 1997;Scherer 
1993;Scherer 2000).  Danzon therefore defined the drug by active ingredient, i.e. molecule (MOL), and ATC 
without regard to manufacturer and brand name.  All forms of a given molecule, including generics and licensed 
products, are combined to form a weighted average price per MOL/ATC.  Differences between products with 
identical MOL and ATC are ignored, but this is presumed to be much less problematic than failing to sample 
substitutes and all forms and strengths. 
 
The IMS Health measure that meets the criteria of being available for all dosage forms and strengths is the 
IMS Standard Unit (SU), which defines a single dose as one tablet or capsule, five milliliters of a liquid (i.e. one 
teaspoon), or one ampoule or vial of an injectable product (IMS 2002; 2005b).  Aggregation of all dosage forms, 
strengths, and packs minimizes sample selection bias.  Danzon and Kim (1998) found that this strategy permits over 
90% of sales to be included for the US, the UK and Canada, and encompasses over two-thirds of sales for most other 
countries.  Therefore, price (Leusuprice) is the average price per standard unit for each ATC/molecule, defined as 
the volume-weighted average retail price over all forms and packs.  Local currency prices are converted to euros by 
IMS Health using constant exchange rates, which minimize effects of exchange rate fluctuations.  
 
Quasi-Hedonic Price Regressions 
 
The first step is to estimate the quasi-hedonic regressions in order to generate price measures that control 
for variation in characteristics of the drug. The semi-log model is adapted, 
 
tjkktjjttjktjk ucXP ,,,,,,,ln   ,  
 
where lnPk,j,t  is the log price per SU for molecule k in country j and year t, X is a vector of quality and market 
characteristics for that molecule, country and year t, γt is year indicators, δj is country indicators, θj,t is an interaction 
between indicators for country j and year t, ck  is an indicator for molecule k, and uk,j,t  is the remaining error, which 
represents cross country price differences that cannot be explained by observable drug characteristics, specific 
molecules available and average year-specific price differences. The second step uses the residuals from these 
regressions as the prices in the price convergence regressions.  
 
Panel Data Unit Root Test 
 
As it is explained above, quasi-hedonic price regressions (without time, country and time-country 
interaction indicators) are used to form the dependent variable in the price convergence equations.  In particular, the 
residuals capture price variation that cannot be attributed to observable characteristics, trends in price differences 
specific to country pairs, or specific molecules.  These thus form the relevant prices in the price convergence 
regressions.  Goldberg and Verboven (2005) used a similar method to test price convergence in the EU car market. 
 
A common approach to examining price convergence is to apply a unit root test to determine whether price 
differential series are stationary, i.e. have mean and variance that do not vary systematically over time and are thus 
stable.  The rejection of the unit root hypothesis implies that relative prices have stationary time series and will thus 
converge in the long run.  Failure to reject the unit root hypothesis implies that relative prices follow a random path, 
so that any deviation from a single price becomes permanent (Fan and Wei 2006).  Moreover, presence of a unit root 
implies that a shock today has a long lasting impact, determining whether a process has a unit root is of interest in its 
own right.  Unit root tests for a single time series, such as the often used Augmented-Dickey Fuller test, have low 
power in the sense that they too often reject stationarity.  Levin et al. (2002) showed that use of a unit root test for 
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panel data can significantly increase test power (Maddala 1999;Maddala and Wu 1999).  Their model assumes that 
each panel unit shares the same AR(1) coefficient, but allows for individual and time effects and a time trend.  This 
test may be viewed as a pooled Dickey-Fuller test or an Augmented Dickey-Fuller test when lags are included, with 
the null hypothesis of nonstationary (Bornhorst and Baum 2001). 
 
The following convergence equations are based on the panel data unit root test developed by Levin and Lin 
(1992;Levin and Lin 1993) and Levin et al. (2002): 
Model 1: 
tjkltjk
L
l
ltjktjk ppp ,,,,
1
1,,,,   

   
Model 2: 
tjkltjk
L
l
ltjkjktjk ppp ,,,,
1
1,,,,,   

   
Model 3: 
tjkltjk
L
l
ltjkjktjk ptpp ,,,,
1
1,,,,,   

   
 
In model 1, the null hypothesis H0: β = 0 is tested against the alternative H1: β < 0. 
 
In model 2, individual molecule/country fixed effects are added, and H0: β = 0 and αj,k = 0 is tested against H1: β < 0 
and αj,k ≠ 0. 
 
In model 3, a time trend is added, and H0: β=0 and δ=0 is tested against H1: β <0 and δ ≠ 0.    
 
These three models serve different purposes. The first is used to test the absolute version of the Law of One 
Price, while the second model is used to test the relative version of the Law of One Price.  Model 3 is not preferred 
in the literature but it is estimated for both adjusted and unadjusted price convergence estimations to compare the 
results.  For series that have clear time trends, the process must be modified to test for unit roots.  A trend stationary 
process can be mistaken for unit root process if we do not control for a time trend.  
 
The convergence equation dependent variable represents the first difference in the log-price of molecule k 
in country j.  This first difference is specified relative to a base country in one specification, and relative to the cross 
country average in another.  In other words, if q represents log price, the two dependent variable specifications are 
 
1) 1,,,,,,  tjktjktjk ppp , where tyBaseCountrktjktjk qqp ,,,,,,   and p k,BaseCountry,t = 1;  
 
2) 1,,,,,,  tjktjktjk ppp  with tjryaverageCrosscounttjktjk qqp ,,,,,,  .  
 
The test for unit roots relates the first difference to the log price of the previous period; if the coefficient of 
the previous period’s price is negative, price differentials across countries become smaller over time (β <0) and the 
hypothesis of a unit root is rejected. Therefore, β denotes the speed of convergence.  Under the null hypothesis of no 
convergence, β = 0 and a shock to pk,j,t is permanent (i.e. has a unit root).  If β ≥ 0, the price differential is non-
stationary, implying persistent price divergence.  If β < 0, prices converge.  The coefficient estimate is tested 
according to the critical values reported in Levin and Lin (1992, 1993) and t-star statistics (adjusted t statistics, 
tabulated in Levin et al. 2002) are also reported. After transformation by factors provided by Levin and Lin (1992, 
1993), the t-star statistic is distributed standard normal under the null hypothesis of nonstationarity. The half-life of a 
shock to the price differential is 
)1ln(
)2ln(


. 
 
Model 2, used to test the relative version of the Law of One Price, is the primary focus of this study.  The 
αk,j capture price differences that are specific to country pairs and molecules.  Large values would indicate market 
segmentation.  Even in integrated markets, some permanent cross-country price dispersion might remain, reflecting 
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local factors that cannot be arbitraged away.  If this dispersion fully explains any price differentials, the relative 
version of the Law of One Price holds.  If instead prices of identical products are equal across countries, the absolute 
version of the law of one price holds (Goldberg and Verboven 2004).  Dividing these fixed effects by –β yields the 
long-term systematic price differentials across countries.  For brevity, the average αj,k across molecules by country is 
reported. 
 
The lags (L) 
ltjkp  ,,  are used to account for possible serial correlation in the error term.  Because of the 
limited number of years available in the data set, the estimations include lags of zero, one or two years, consistent 
with previous studies.  In addition to these, Campbell and Perron’s top-down approach (Pammolli, et al. 2004) is 
also used to find optimum amount of lag order when the equations are estimated.  In this approach, the lag order is 
set to a maximum of two lags for each molecule/country estimation.  If the absolute value of the t-statistic of γ2 is 
less than 1.96, the lag order is set to one lag and the equation is re-estimated.  If this t-statistic is less than 1.96, no 
lags are included. 
 
FINDINGS/ RESULTS 
 
The results from the quasi-hedonic regressions suggest that bilateral drug price differences are decreasing. 
Although price differences still exist because of diverging health system regulations, market integration and 
continued coordination efforts of the European Commission, they indicate that there is a movement towards a single 
pharmaceutical market in the EU (Timur, et al. 2010). However, our focus in this preliminary study is not the price 
differences, instead empirical evidence on price convergence.  
 
The regression coefficients provide estimates of the speed of the convergence to the law of one price, 
which indicates how quickly deviations from long term price differentials are eliminated. Table 1 reports estimation 
results with Spain and Germany as base countries. The Hausman test rejects the null hypothesis of fixed and random 
effects equivalence, thus fixed effects models are used to form the dependent variables for the convergence 
equations.  The results are robust for zero, one and two lags, in addition to the Campbell and Perron (1992) top 
down approach, with the latter reported in the tables.  
 
 
Table 1 
Results for Price Convergence Estimations for All Molecules (Adjusted by FE) 
 Model 1 Model 2 
Dependent Variable: ΔPi,k,t Base: SPN Base: GR Base: SPN Base: GR 
β1 0.01 -0.02 -0.18 -0.17 
Half-life of Shock (in years) - 34.3 3.5 4.4 
FR2 - - 0.02 0.01 
GRb - - 0.08 - 
UKb - - 0.15 0.00 
SPNb - - - -0.08 
ITYb - - 0.06 -0.08 
Lags of ΔPi,k,t Yes(1)
3 Yes(1)c Yes4 Yesd 
t-star 
P>t 
8.89 
1.000 
-19.25 
0.000 
-8.39 
0.000 
-8.34 
0.000 
Molecule/Country Fixed Effects No No Yes Yes 
Time Trend No No No No 
N 2,940 3,210 2,940 3,210 
 
 
                                                 
1 β coefficients are estimated by the Levin et al. (2002) panel unit root test module in StataTM 9.2 (levinlin).  
2 Country fixed effects are estimated for each molecule/country by the Augmented Dickey Fuller regressions in StataTM 9.2 
(dfuller) and then averaged for each country. 
3 The average number of lags for each molecule/country is 1.  
4
 The number of lags is determined by using the Campbell and Perron top-down approach.  
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Model 1 does not include molecule/country fixed effects and thus tests for convergence to the absolute 
version of the law of one price.  The null hypothesis is that the price differences converge toward zero in the long 
run, i.e. β < 0.  The β coefficient is negative in the specification where Germany is the base country, with an implied 
half-life of a shock, i.e. –ln(2)/ln(1+β), of 34.3 years.  This half-life of 34.3 years is longer than the typical life cycle 
of a drug and provides little, if any evidence of convergence.  When Spain is the base country, the β coefficient is 
positive, indicating that there is no evidence of the absolute version of law of one price holding.  The positive sign of 
the coefficient actually implies persistent price divergence.  The results are mostly consistent with the international 
trade literature.  
 
Model 2 tests the relative version of the law of one price and finds estimated β ranges between –0.17 and –
0.18.  Based on the adjusted t statistics (t-star) values, the unit root hypothesis is rejected, signifying significant 
evidence of price convergence. The implied half-lives of shocks, according to these β estimates, are between 3.5 and 
4.4 years.  These half-lives are longer than found in the recent international trade literature (Goldberg and Verboven 
2005). 
 
The αi,k in model 2 captures molecule country fixed effects that account for non-time dependent, molecule 
specific price differences across countries. Such effects could include transportation costs, unobserved quality 
differences that vary by destination, or markup differences. The presence of molecule/country fixed effects in the 
estimations implies testing the relative version of law of one price. The average molecule/country specific fixed 
effects are displayed in table 1. These large values of molecule/country fixed effects indicate market segmentation 
even if the relative version of law of one price holds in the data, consistent with other studies in the literature.  By 
dividing the fixed effects by –β, long-term systematic price differences relative to Spain of 83% for the UK, 33% for 
Italy, 11% for France, and 44% for Germany are obtained.  When Germany is the base country, long term price 
differentials are 6% for France, 0% for the UK, and –47% for Spain and Italy.  
 
Similar convergence coefficients are obtained for both the absolute and the relative version of law of one 
price, using prices from random effect models (table 2).   
 
 
Table 2 
Results for Price Convergence Estimations for All Molecules (Adjusted by RE) 
 Model 1 Model 2 
Dependent Variable: ΔPi,k,t Base: SPN Base: GR Base: SPN Base: GR 
β5 0.01 -0.02 -0.19 -0.18 
Half-life of Shock (in years) - 34.3 3.3 3.5 
FR6 - - 0.02 0.00 
GRb - - 0.09 - 
UKb - - 0.10 0.00 
SPNb - - - -0.09 
ITYb - - 0.07 -0.07 
Lags of ΔPi,k,t Yes(1)
7 Yes(1)c Yes8 Yesd 
t-star 
P>t 
8.80 
1.000 
-19.89 
0.000 
-8.92 
0.000 
-8.16 
0.000 
Molecule/Country Fixed Effects No No Yes Yes 
Time Trend No No No No 
N 2,940 3,210 2,940 3,210 
 
 
 
 
                                                 
5 β coefficients are estimated by the Levin et al. (1992) panel unit root test module in StataTM 9.2 (levinlin).  
6 Country fixed effects are estimated for each molecule/country by the Augmented Dickey Fuller unit root test module in StataTM 
9.2 (dfuller) and then averaged for each country. 
7 The average number of lags for each molecule/country is 1.  
8 The number of lags is determined by using the Campbell and Perron top-down approach.  
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Slightly smaller molecule/country price differentials emerge, which are higher than Spain by 11% for 
France, 47% for Germany, 53% for the UK and 37% for Italy, and lower than Germany by 50% for Spain, 39% for 
Italy, 0% for France and the United Kingdom. In addition, all specifications are also estimated using model 3, which 
includes a time trend. The expected results, that the deviations from the long term differences are eliminated in 
approximately a year, are obtained.  This is shorter than without the time trend in model 2, but the long term price 
differences remain about the same.  
 
In addition, the same hypotheses are tested for unadjusted prices.  In this case, model 3, which includes a 
time trend, is also reported in the tables for comparison purposes.  Table 3 reports the results for the three models.  
The results remain robust for the absolute version of the law of one price. In model 2, the estimated rates of 
convergence are very similar to the adjusted price estimates, but molecule/country fixed effects show very high price 
differences which are expected due to not accounting for quality adjustments.   
 
 
Table 3 
Results for Price Convergence Estimations for All Molecules (Unadjusted) 
 Model 1 Model 2 Model 3 
Dependent 
Variable: ΔPi,k,t 
Base: 
SPN 
Base: 
GR 
No 
Base 
Base: 
SPN 
Base: 
GR 
No 
Base 
Base: 
SPN 
Base: 
GR 
No 
Base 
βa -0.00 -0.01 0.00 -0.33 -0.14 -0.30 -0.77 -0.68 -0.65 
FRb - - - 0.16 -0.02 -0.66 0.16 -0.02 -0.90 
GRb - - - 0.02 - -0.32 0.02 - -0.44 
UKb - - - -0.17 0.02 -0.25 -0.17 -0.17 -0.81 
SPNb - - - - -0.19 -1.08 - -0.79 -1.50 
ITYb - - - 0.06 -0.00 -0.35 0.06 -0.30 -0.94 
Lags of ΔPi,k,t Yes(1)
c Yes(1) Yes(1) Yes(1) Yes(1) Yes(1) Yes(1) Yes(1) Yes(1) 
t-star 
p>t 
-14.19 
0.000 
-8.52 
0.000 
0.18 
0.575 
-30.00 
0.000 
-15.82 
0.000 
-30.78 
0.000 
-94.37 
0.000 
-27.88 
0.000 
-41.37 
0.000 
Molecule/Country Fixed 
Effects 
No No No Yes Yes Yes Yes Yes Yes 
Time Dummies No No No No No No Yes Yes Yes 
N 2940 3210 3790 2940 3210 3790 2940 3210 3790 
 
 
CONCLUSION/DISCUSSION 
 
Controlling for variation in quality and market characteristics across countries, both the absolute and 
relative versions of the law of one price are tested by employing panel data unit root tests.  Price convergence is 
expected in integrated markets like the European Union, but factors like transportation costs, tax differences and 
regulatory regimes that vary across countries, might produce fixed country-specific price differences.  The relative 
version of the law of one price states that these price gaps tend to return to some long-run level over time, even if 
this level is not zero. Despite the fact that the data in this analysis control for observable quality and market 
characteristics, systematic price differences across countries could persist because of the nature of the 
pharmaceutical market and differences across countries with regard to demographics, culture and medicine 
consumption attitudes. 
 
For the absolute version, the half life of a shock is 34 years, indicating very slow convergence.  The main 
interest in this study is not the absolute version of the law of price because it is expected that cross country drug 
price differences cannot be completely eliminated.  Results provide evidence in support of the relative version of the 
law of one price, which is a narrower definition of price convergence and is the key interest of the study.  For the 
relative version, half lives are between 3 and 5 years.  The estimated rates of convergence in the EU pharmaceutical 
                                                 
a β coefficients are estimated by Levin et al. (2002) panel unit root test module in StataTM 9.2 (levinlin). 
b Country fixed effects are estimated for each molecule/country by Augmented Dickey Fuller regressions (dfuller) in StataTM 9.2 
and then averaged for each country.  
c The average number of lags for each molecule/country is 1.  
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industry are comparatively slower than the rates for analogous studies of different European industries, e.g. half 
lives of 1.3–1.6 years in the automobile industry.  This could be explained by the different health care systems, 
pricing and reimbursement regulations by the national governments across countries.  
 
Long term price differentials imputed from the estimated molecule/country fixed effects show price 
differences across markets between 0% and 40% for countries other than the UK, providing evidence of market 
segmentation. Possible sources of the larger long term price differences between the UK and other countries include 
the fact that the UK is not a member of the “euro zone”, transportation costs (e.g. the UK is not contiguous like the 
other nations) and other different policies by the UK government.  According to Kotzian (2004), the reason for these 
price differences could be the political arena in the EU: some governments grant high prices for newly introduced 
products to encourage therapeutic innovations, others set a very low price due to health care budget concerns.    
 
This preliminary study contributes new results to the existing literature on European integration and 
pharmaceutical price convergence.  The results show that even though the pharmaceutical industry is one of the 
most heavily regulated markets with divergent methods in the EU and there are no legislative actions by the 
European Commission for the pharmaceutical industry toward a single market, price differences across countries do 
converge over time, albeit relatively slowly, conditional on the molecule/country fixed effects.  Although price 
differences still exist, progress toward the single pharmaceutical market is evident.  Possible explanation could be: 
International reference pricing that create spillover of price levels from one country to another, parallel imports 
across the EU countries and continuous coordination affords by the European Commission.  
 
The unique molecule level data set in this paper includes branded drugs along with generics, licensed, 
OTCs and parallel imports, and allows controlling for quality and market characteristics.  The empirical results not 
only demonstrate consistent decrease in the prices overall but also provide evidence of relative price convergence in 
the pharmaceutical industry.  As is emphasized by the European Commission there is no reason to exempt 
pharmaceuticals from the single market ideal. 
 
Finally, this study attempts to be the first preliminary empirical investigation of the drug price convergence 
in the EU. This research has also several limitations that should be noted.  First, the data set analyzed in this study 
spans only ten years.  Several other studies in the literature use periods of similar length, but as with all time series, a 
longer series would permit a stronger test of the price convergence hypothesis.  It would also allow for testing 
whether molecule/country effects are declining over time and if the speed of convergence has changed over time. 
Second, since IMS fixed euro standard unit prices are used to flatten exchange rate fluctuations, the role of exchange 
rate changes must be investigated separately.  
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